APLS missed EPS expectations by 21.01%
Feb 24, 2026, 11:34 PM
0.00%
What does APLS do
Apellis Pharmaceuticals, based in Waltham, Massachusetts, specializes in developing therapies for diseases with high unmet needs, employing 702 staff since its IPO in November 2017. Its approved products include SYFOVRE for geographic atrophy and pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
Apellis Pharmaceuticals (APLS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Apellis Pharmaceuticals's actual EPS was -$0.47, missing the estimate of -$0.39 per share, resulting in a -21.01% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.